Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma

F. H. Dexeus, C. J. Logothetis, A. Sella, K. Fitz, R. Amato, J. M. Reuben, N. Dozier

Research output: Contribution to journalArticlepeer-review

Abstract

Fifty patients with locally advanced or metastatic renal cell carcinoma were treated with coumarin (1,2-benzopyrone) at 100 mg orally daily starting on day 1 and cimetidine 300 mg orally four times a day starting on day 15. When disease progressed, coumarin was escalated to 100 mg orally four times a day. Three patients (6%; 95% confidence interval [CI], 2% to 17%) achieved a partial response, one of those after dose escalation. In addition, one patient had a minor response, then progressing disease, and again had a minor response after dose escalation. All four responders had nonassessable primary tumors (three had had prior nephrectomy and one a renal angioinfarction). The only major toxicity was renal (37 patients had minor to moderate elevations in serum creatinine level). Immunologic studies (hypersensitivity skin testing, lymphocyte blastogenesis response, number of lymphocytes, T lymphocytes, T helper and T suppressor subsets, and T helper:suppressor ratio), performed before and after therapy, showed a relative lymphopenia and decreased hypersensitivity skin-testing results at baseline, and a general decline over time in the number of T cells and T helper and T suppressor subsets. There was no enhancement in any of the immunologic parameters tested. The response rate was 6%, lower than previously reported; a general immunodeficiency was noted at baseline, and the lymphopenia worsened with progressing disease, unaffected by therapy.

Original languageEnglish
Pages (from-to)325-329
Number of pages5
JournalJournal of Clinical Oncology
Volume8
Issue number2
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Dive into the research topics of 'Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this